Age-related Macular Degeneration Market Outlook:
Age-related Macular Degeneration Market size was over USD 11.66 billion in 2025 and is projected to reach USD 24.03 billion by 2035, growing at around 7.5% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of age-related macular degeneration is evaluated at USD 12.45 billion.
Age-related macular degeneration is a frequent disorder among the elderly population that progresses over time. The prevalence of age-related macular degeneration is on the rise worldwide, partly due to the expanding elderly population. Therapeutics to address the disease are thus in great demand. Taking advantage of this chance, pharmaceutical companies are concentrating on developing medications to cure age-related macular degeneration. At this point, there will be 1.4 billion people over the age of 60, up from 1 billion in 2020. The number of persons sixty years of age and older will quadruple globally by 2050. It is anticipated that between 2020 and 2050, the number of people 80 years of age or older will triple, reaching 426 million.
New therapeutic techniques, such as gene therapy and long-acting anti-VEGF injections, provide prospects for better patient convenience and better results. Advances in diagnostic imaging methods such as optical coherence tomography allow for earlier detection and intervention, which in turn improves therapy efficacy.
